Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms.
OBJECTIVE
To investigate the possible relationship between the bladder mucosal expression of α(1)-adrenoceptor (AR) mRNAs, storage symptoms and urodynamic findings in patients with lower urinary symptoms (LUTS) and benign prostatic obstruction (BPO).


METHODS
Mucosa was obtained from the posterior bladder wall from 20 patients with a diagnosis of LUTS and BPO undergoing prostatectomy. α(1)-AR subtype mRNA was quantified using competitive real-time reverse transcription-polymerase chain reaction. A preoperative video urodynamic study measured volumes for first desire to void (FDV) and strong desire to void (SDV). Patients were divided into group 1, with volumes for FDV ≤ 200 ml or SDV ≤ 300 ml, and group 2, with volumes FDV ≥ 201 ml and SDV ≥ 301 ml. Preoperative and postoperative international prostate symptom score (IPSS) and Overactive Bladder Symptom Score (OABSS) were evaluated.


RESULTS
The group 1 FDV (141.0 ± 13.5 ml) was significantly lower than that of group 2 (299.0 ± 48.1 ml). Similarly, the SDV for group 1 (247.0 ± 21.9 ml) was also significantly lower than for group 2 (444.0 ± 32.5 ml). There were no significant differences between groups 1 and 2 with respect to mucosal α(1a)- and α(1b)-AR mRNA levels. However, group 1 patients had significantly more α(1d)-mRNA than those in group 2. No relationship between the expression of α(1)-AR mRNAs and preoperative or postoperative OABSS or IPSS was detected.


CONCLUSIONS
There was a relationship between the expression of α(1d)-AR mRNA in the bladder mucosa and storage-phase urodynamics in LUTS/BPO patients, suggesting a role of α(1D)-ARs in bladder sensation.
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan.
Yoshiki
Y
Kurizaki
Osamu
O
Ishizuka
Tetsuya
T
Imamura
Midori
M
Ichino
Teruyuki
T
Ogawa
Yasuhiko
Y
Igawa
Osamu
O
Nishizawa
Karl-Erik
KE
Andersson
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000494:pharmacology; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D012333:RNA, Messenger / Q000378:metabolism*; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000378:metabolism*; D012189:Retrospective Studies; D001743:Urinary Bladder / Q000378:metabolism*; D001748:Urinary Bladder Neck Obstruction / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000378:metabolism / Q000503:physiopathology; D014563:Urodynamics / Q000502:physiology*; D014570:Urologic Diseases / Q000378:metabolism* / Q000503:physiopathology*
D058668:Adrenergic alpha-1 Receptor Antagonists; D015415:Biomarkers; D012333:RNA, Messenger; D018340:Receptors, Adrenergic, alpha-1